Crispr gene editing treatment from Intellia succeeds in Phase 3 trial

Crispr gene editing treatment from Intellia succeeds in Phase 3 trial

Intellia Therapeutics, constructing exterior and firm signal, Cambridge, Massachusetts, USA. Spencer Grant | Universal Images Group | Getty Images Intellia Therapeutics stated its Crispr-based treatment for a uncommon swelling situation met its objectives in a late-stage trial, marking a milestone for the sector of gene editing and placing the corporate on monitor to hunt approval…

Read Full News
Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing

Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing

Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) met major and all key secondary endpoints; favorable security and tolerability information noticed Single dose of lonvo-z freed most sufferers from each assaults and ongoing remedy for six-month efficacy analysis interval, demonstrating its potential to be the primary and solely one-time HAE therapy Rolling biologics license software…

Read Full News